Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects
in DNA repair. Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with …

Intratumor heterogeneity is a key factor contributing to therapeutic failure and, hence,
cancer lethality. Heterogeneous tumors show partial therapy responses, allowing for the …

New opportunities are needed to increase immune checkpoint blockade (ICB) benefit.
Whereas the interferon (IFN)γ pathway harbors both ICB resistance factors and therapeutic …

Observations from cultured cells 1 , 2 , 3 , animal models 4 and patients 5 , 6 , 7 raise the
possibility that the dependency of tumours on the therapeutic drugs to which they have …

We are witnessing several revolutionary technological advances in cancer. These
innovations have not only contributed to a growing understanding of the tumor and its …

Melanomas can switch to a dedifferentiated cell state upon exposure to cytotoxic T cells.
However, it is unclear whether such tumor cells pre-exist in patients and whether they can be …

The cytokine IFNγ differentially impacts on tumors upon immune checkpoint blockade (ICB).
Despite our understanding of downstream signaling events, less is known about regulation …

These findings show that targeting AXL-positive tumor fractions with an antibody–drug
conjugate enhances antitumor immunity in several humanized tumor models of melanoma and …

Genes limiting T cell antitumor activity may serve as therapeutic targets. It has not been
systematically studied whether there are regulators that uniquely or broadly contribute to T cell …

10.7554/eLife.43668.001 Human lung adenocarcinoma exhibits a propensity for de-differentiation,
complicating diagnosis and treatment, and predicting poorer patient survival. In …